Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer-Reference-Cited by-同舟云学术

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer

Published:2020-02 Issue: Volume:140 Page:46-54
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Pruis M.A.^ORCID,Geurts-Giele W.R.R.,von der Thüsen J.H.^ORCID,Meijssen I.C.,Dinjens W.N.M.,Aerts J.G.J.V.,Dingemans A.M.C.,Lolkema M.P.,Paats M.S.,Dubbink H.J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN;Ferlay;Int. J. Cancer,2012

2. EGFR tyrosine kinase inhibitors in lung Cancer: an evolving story;Lecia;Annu. Rev. Med.,2008

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013

5. Comprehensive molecular profiling of lung adenocarcinoma;Cancer Genome Atlas Research N;Nature,2014

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01

2. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies;JTO Clinical and Research Reports;2023-10

3. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations;Current Oncology;2023-09-27

4. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer;The Oncologist;2023-06-01

5. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy;European Journal of Cancer;2023-03